An Open-Label, Randomized, Three-Period Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect of JNJ-54861911 Tablet (1x25mg) After Single Dose Administration in Healthy Elderly Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2017
At a glance
- Drugs JNJ 54861911 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 24 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 06 Feb 2015 New trial record